Related Experiment Video
Updated: Dec 26, 2025

Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure
Published on: May 27, 2022
Fungaemia due to rare yeasts in a tertiary care university centre within 18 years
Sehnaz Alp1, Dolunay Gulmez2, Caglayan Merve Ayaz1
1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Background:
Fungaemia due to rare yeasts has been recognised as an emerging, clinically relevant, but less investigated condition. Intrinsic resistance or reduced susceptibility of these species to echinocandins or fluconazole remains as a challenge in empirical treatment.
Objectives:
To describe the clinical characteristics, administered antifungal agents, outcomes of patients with rare yeasts other than Candida (RY-OTC) fungaemia and determine the antifungal susceptibility profiles of the isolates.
Patients And Methods:
RY-OTC fungaemia between January-2001 and December-2018 were retrospectively evaluated. Antifungal susceptibility tests were performed according to CLSI M27-A3.
Results:
We identified 19 patients with fungaemia due to 20 RY-OTC (8 Trichosporon asahii, 4 Cryptococcus neoformans, 4 Saprochaete capitata, 3 Rhodotorula mucilaginosa, 1 Trichosporon mucoides) with an incidence of 2.2% among 859 fungaemia episodes. Haematological malignancy was the most common (42%) underlying disorder. In 6 patients, RY-OTC fungaemia developed as breakthrough infection while receiving echinocandins, amphotericin B or fluconazole. Amphotericin B, fluconazole or voriconazole were the drugs of choice for the initial treatment of breakthrough fungaemia. Among patients without previous exposure to antifungals, the most common empirical treatment was an echinocandin (50%), followed by fluconazole (42%) and amphotericin B (8%). Overall mortality was 47%. Worse outcome was most common among patients receiving echinocandins (83% vs 25%, P < .05). Voriconazole and posaconazole showed the highest in vitro activity against all the isolates tested. Amphotericin B MICs were relatively higher and the degree of activity of fluconazole and itraconazole was variable.
Conclusions:
Early recognition of RY-OTC and knowledge about their susceptibility patterns remain crucial in initial treatment pending susceptibility data of isolates.
Insights
Rare yeast fungaemia (RY-OTC) presents treatment challenges due to antifungal resistance. Voriconazole and posaconazole show promising in vitro activity against these emerging pathogens.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Microbiology
Background:
- Fungaemia caused by rare yeasts (RY-OTC) is an emerging, understudied condition.
- Intrinsic resistance of RY-OTC to common antifungals like echinocandins and fluconazole complicates empirical treatment strategies.
Purpose of the Study:
- To characterize the clinical features of patients with RY-OTC fungaemia.
- To document antifungal agents used and patient outcomes.
- To determine the in vitro antifungal susceptibility profiles of RY-OTC isolates.
Main Methods:
- Retrospective evaluation of RY-OTC fungaemia cases from January 2001 to December 2018.
- Antifungal susceptibility testing performed using CLSI M27-A3 guidelines.
Main Results:
- Nineteen patients experienced 20 RY-OTC fungaemia episodes, accounting for 2.2% of all fungaemia cases.
- Haematological malignancy was the most frequent underlying condition (42%).
- Breakthrough fungaemia occurred in 6 patients on echinocandins, amphotericin B, or fluconazole. Voriconazole and posaconazole demonstrated superior in vitro activity against tested isolates, while amphotericin B MICs were higher and azole activity varied.
Conclusions:
- Prompt identification of RY-OTC infections is critical.
- Understanding the susceptibility patterns of rare yeasts is essential for guiding initial antifungal therapy.
- Worse outcomes were associated with echinocandin use in breakthrough infections.
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Ascomycota
Fungal Phylum Microsporidia
Overview of Fungi
Fungal Phylum Basidiomycota

